Inclusion-Body Myositis (IBM)

AAN Releases Guidelines for IVIG in Some Neuromuscular Diseases

The American Academy of Neurology (AAN) has released new guidelines on the use of a treatment called intravenous immunoglobulins (IVIG) in various neuromuscular disorders.

MDA 2012 Conference Report: Genetics and Immunology Update

More than 500 physicians, allied health care professionals and MDA staff attended the MDA's 2012 Clinical Conference in Las Vegas, March 4-7.

The program emphasized:

MDA Commits $12 Million to Neuromuscular Disease Research

The Muscular Dystrophy Association has awarded 38 new grants totaling more than $12 million to fund research projects focused on its continuing mission to uncover the causes of, and develop therapies for, the more than 40 neuromuscular diseases in its program.

MDA's Board of Directors reviewed and approved the new grants based on recommendations from the Association's Scientific and Medical Advisory Committees, and the grants took effect Feb. 1.

IBM - Sanford Bernstein, Ph.D.

Sanford Bernstein, a professor of biology at San Diego State University in California, was awarded an MDA research grant totaling $370,311 over a period of three years. The funds will help support Bernstein's research into the underlying molecular causes of, and potential treatments for, inclusion-body myopathy type 3 (IBM-3).

IBM-3 is caused by a mutation in a protein called myosin, the "molecular motor" that drives muscle contraction.

Seeking Participants for hIBM/GNE Clinical Trial

Update (Feb. 11, 2013): The phase 2 trial is no longer recruiting participants.

MDA Awards $13.7 Million in Research Grants

The Muscular Dystrophy Association has awarded 40 research grants totaling $13.7 million to advance the understanding of disease processes and uncover new strategies for treatments and cures of muscular dystrophy and the more than 40 other diseases in the Association's program.

The new grants were recommended by MDA's Scientific and Medical Advisory Committees and approved by MDA's Board of Directors at its July 2011 meeting.

William Titus

Location

Watchung, NJ

William was a licensed surveyor and founded his own surveying business. Upon his retirement in 1995, he began painting. His subjects were “vintage Watchung sites,” and many of his paintings are on display at the Watchung Police Station. This artwork recalls William and his teenage friends sledding on Hillcrest Road in Watchung around 1949. This artwork was featured in the MDA 2003 Holiday Wishes card collection.

Full name: 
William Titus
Artist: 
William Titus
Medium: 
Oil

Frank Bare

Location

Mesquite, NV

Frank began painting ceramics in 1989 and then expanded into acrylics on canvas. He received both bachelor’s and master’s degrees from the University of Illinois, where he competed in gymnastics and received many NCAA awards. Frank served as the Executive Director of the U.S. Gymnastics Federation for many years and currently serves as the chairman of the Board for the International Hall of Fame.

Full name: 
Frank Bare
Artist: 
Frank Bare
Medium: 
Acrylic

Mike Shirk

Location

San Diego, CA

Mike spent 40 years as an advertising copy writer. His hobbies included hiking and distance running. In 2000, Mike began painting, and as a watercolorist, he revisits the outdoor landscapes he loves, but with a brush and palette instead of hiking boots and sneakers. He is a member of the San Diego Watercolor Society.

Full name: 
Mike Shirk
Artist: 
Mike Shirk
Medium: 
Watercolor

Clinical Trials

About clinical trials

A clinical trial is a test in humans of an experimental medication or therapy. Clinical trials are experiments, not treatments, and participation requires careful consideration.

Although it's possible to benefit from participating in a clinical trial, it's also possible that no benefit — or even harm — may occur. Keep your MDA clinic doctor informed about any clinical trial participation. (Note that MDA has no ability to influence who is chosen to participate in a clinical trial.)

Pages

MDA in Your Community